Received Oct 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLU4 | INFLUENZA (SEASONAL) (FLULAVAL QUADRIVALENT) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | — | — |
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
Inadvertent Administration After a vaccine Temperature Excursion; This non-serious case was reported by a other health professional via call center representative and described the occurrence of incorrect storage of drug in a patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis. Co-suspect products included HAV (Havrix) for prophylaxis, DTPa (Reduced antigen) (Boostrix) for prophylaxis and Flu Seasonal QIV Quebec (FluLaval Quadrivalent) for prophylaxis. On an unknown date, the patient received Menveo, Havrix, Boostrix and FluLaval Quadrivalent. On an unknown date, an unknown time after receiving Menveo, Havrix, Boostrix and FluLaval Quadrivalent, the patient experienced incorrect storage of drug (Verbatim: Inadvertent Administration After a vaccine Temperature Excursion). The outcome of the incorrect storage of drug was not applicable. Additional Information: GSK receipt date: 22-SEP-2025 Medical assistant reported that the vaccines Infanrix, Pediarix, Kinrix, Havrix, Engerix-B, Flulaval, Menveo, Bexsero, Priorix, Rotarix, Boostrix were experienced a temperature excursion below the normal range on 19th September 2025, having lowest temperature reached at 0.3 degree Celsius.and excursion lasted for:1hr and 33 min. There was not any prior excursions. There were 4 possible 4 vaccines that has been administered to patients including Menveo, Havrix, Boostrix, Flulaval TIV. The batch number was not provided and a request for this information has been made.